Hodgkin Lymphoma

Clinical Trials

Below is a list of Hodgkin Lymphoma clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Phase 3 Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease
Patients are being asked to take part in this study because they have a type of cancer called Hodgkin disease, a type of lymphoma (cancer of the lymph system). The lymph system is made up of tissue throughout the body that makes and stores infection-fighting cells. Hodgkin disease is one of the most treatable and curable childhood cancers. The standard treatment for Hodgkin disease involves chemotherapy (treatment with anti-cancer drugs) and radiation therapy (the use of high-dose x-rays to kill cancer cells).

Although patients are cured from their cancer, some experience bad effects from treatment later in life. These kinds of side effects are often referred to as "late effects."
This can include problems with growth, problems with some organ functions, and sometimes another cancer develops. It is thought that if some patients can be successfully treated with less intense therapy, those patients might have less bad effects later in life.
In this study, patients whose disease goes away after initial treatment with three cycles of chemotherapy (anti-cancer drugs) will be done with treatment. They will not have any radiation. Treatment without radiation therapy is considered the experimental treatment on this study. Patients whose disease does not go away after initial treatment with three cycles of chemotherapy will have radiation therapy.

If patients only have chemotherapy on this study, and their disease is suspected to have returned, then the study doctors will arrange for a biopsy in order to determine whether or
not their disease has returned. If their disease returns after going away (this is called a relapse) the study doctors will look at how widespread the relapse is, and certain other
symptoms, in order to find out if a patient has a low-risk or a high-risk relapse. Low risk
means their disease has only returned in a few lymph nodes and they have no symptoms like fever, drenching night sweats and/or weight loss. High risk means their disease is in many places and they have symptoms like fever, drenching night sweats and/or weight loss. If a patient has a high-risk relapse, they will be taken off all study therapy and their study doctor will talk to the patient about other treatment options. If they have a low-risk relapse, the research staff will ask the patient to take part in the second part of this study. If patients agree to take part, they will be given additional chemotherapy and radiation. The relapse treatment they will get will be less intensive than the standard relapse treatment and is also considered experimental treatment.
Read more

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib (Bay 43-9006) in Combination with the mTOR Inhibitor RAD001 (Everolimus, Certican) in Patients with Relapsed Non-Hodgkins Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma
Sorafenib and RAD001 are two drugs that block some of the main switch pathways in tumor cells from working properly. When combined, it is hoped that they might prevent the cells from growing or cause them to die. Preliminary experiments with RAD001 in lymphoma patients have shown definite anti-tumor activity.
Read more

AHOD0521, A Phase II Study of Bortezomib (Velcade, PS-341, IND #58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease
Patients are being asked to take part in this research study because they have been diagnosed with Hodgkin disease that did not get better (refractory) or that went away and then came back (recurrent) after initial treatment. Refractory and recurrent Hodgkin disease are usually treated with two anti-cancer drugs (chemotherapy)-ifosfamide and vinorelbine. In this study, the researchers would like to add a third anti-cancer drug to that combination. This experimental drug is called bortezomib (velcade). It has been approved by the U.S. Food and Drug Administration (FDA) for the use of adult blood cancer but not for use in children with Hodgkin Disease. Earlier studies on adults and a small group of children show that bortezomib can be given safely and that it seems to work well at killing cancer cells when combined with other anti-cancer drugs. In addition to the treatment goals, the research staff would like to answer some biology research questions that might benefit future patients. Patients can choose to be in this clinical trial without taking part in the biology portion of the study.

It is common to enroll children and adolescents with cancer in a clinical trial that seeks to improve cancer treatment over time. Clinical trials include only people who choose to take part. Patients have a choice between a standard treatment for Hodgkin disease and this clinical trial.


What is the current Standard of Treatment for This Disease?
Hodgkin disease that did not get better or recurs after initial treatment is usually treated with the drug combination of ifosfamide and vinorelbine. These two drugs have worked well at treating recurrent and relapsed Hodgkin disease, but some people don?t respond to these drugs.

Why Is This Study Being Done?
The main goal of this study is to find out what effects, good and/or bad, the drug combination of ifosfamide and vinorelbine with bortezomib has on people with refractory or recurrent Hodgkin disease.

Other goals of this study include:
? To find out if people treated with ifosfamide/vinorelbine with bortezomib do better than those treated with ifosfamide and vinorelbine without bortezomib in a previous study.
? To find out if bortezomib has an effect on the number of blood stem cells collected for stem cell transplantation.
? To collect biologic specimens in order to see how people?s body and cancer respond to ifosfamide/vinorelbine with bortezomib treatment.
Read more

Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
The standard treatment for Hodgkin disease is chemotherapy and radiation therapy (high-dose x-rays). Most patients are cured of their Hodgkin disease, but some people have late effects from the treatment later in life. Late effects can include problems with growth, organ function, and sometimes a second kind of cancer. Late effects may be caused by either chemotherapy or radiation. Researchers believe that if some people can be treated with less treatment or with surgery alone, then these people might have fewer late effects.
This study is being done to:
- See if "late effects" (side effects that show up later in life from the treatment) can be lowered or prevented by using less chemotherapy and radiation.
- Find out if using less chemotherapy and radiation to treat LPHD will still show high cure rates or if cure rates will be lower than with standard treatment.
Read more

Treatment with Anti-CD30 Antibody, MDX-060 Combined with Chemotherapy, Gemcitabine (Gemzar); or MDX-060 in Combination with Dexamethasone (Decadron); or Gemcitabine Alone in Patients with Relapsed (Recurring) or Refractory (Resistant) Hodgkin's Disease
This study is being done to compare the effects (good and bad) of each of the following treatment plans in the treatment of Hodgkin's Disease:
-MDX-060 in combination with gemcitabine
-MDX-060 in combination with dexamethasone
-gemcitabine alone
This study is also being done to see if your quality of life gets better because of the study drug.
MDX-060 is an investigational drug that has not been approved by the Food and Drug Administration (FDA) for standard clinical use. Gemcitabine has been approved by the FDA for the treatment of lung cancer and pancreas cancer, but has not been approved in the combination used in this study, and its use is considered investigational. Dexamethasone has been approved by the FDA for the treatment of pressure and swelling, but has not been approved in the combination used in this study, and its use is considered investigational.
Read more